A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment
Prophylactic vaccination against HIV-1 sexual transmission will probably require antibody elicitation at genital mucosal surfaces. However, HIV-1 envelope glycoprotein (Env)-based antigens are weakly immunogenic, particularly when applied mucosally. The polyanion PRO 2000 is safe for human vaginal a...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Public Library of Science
2011
|
| Subjects: |
| _version_ | 1797075506579898368 |
|---|---|
| author | Wegmann, F Krashias, G Lühn, K Laamanen, K Vieira, S Jeffs, S Shattock, R Sattentau, Q |
| author_facet | Wegmann, F Krashias, G Lühn, K Laamanen, K Vieira, S Jeffs, S Shattock, R Sattentau, Q |
| author_sort | Wegmann, F |
| collection | OXFORD |
| description | Prophylactic vaccination against HIV-1 sexual transmission will probably require antibody elicitation at genital mucosal surfaces. However, HIV-1 envelope glycoprotein (Env)-based antigens are weakly immunogenic, particularly when applied mucosally. The polyanion PRO 2000 is safe for human vaginal application, and thus may represent a potential formulating agent for vaginal delivery of experimental vaccine immunogens. Based upon its biochemical properties, we hypothesized that PRO 2000 might enhance mucosal immunogenicity of HIV-1 envelope glycoprotein (Env)-based antigens, promoting local and systemic immune responses. Vaginal immunization with Env-PRO 2000 resulted in significantly increased titres of Env-specific mucosal IgA and IgG in mice and rabbits, respectively, compared to Env alone, revealing modest but significant mucosal adjuvant activity for PRO 2000. In vitro, PRO 2000 associated with Env, protecting the glycoprotein from proteolytic degradation in human vaginal lavage. Unexpectedly, PRO 2000 antagonized TLR4 activation, suppressing local production of inflammatory cytokines. Since inflammation-mediated recruitment of viral target cells is a major risk factor in HIV-1 transmission, the immune modulatory and anti-inflammatory activities of PRO 2000 combined with its intravaginal safety profile suggests promise as an HIV-1 mucosal vaccine formulating agent. |
| first_indexed | 2024-03-06T23:51:14Z |
| format | Journal article |
| id | oxford-uuid:72acd3d1-9cc3-4179-ae8e-c36a3afe0d7c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:51:14Z |
| publishDate | 2011 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:72acd3d1-9cc3-4179-ae8e-c36a3afe0d7c2022-03-26T19:51:41ZA novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environmentJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:72acd3d1-9cc3-4179-ae8e-c36a3afe0d7cPathologyHIV/AIDSEnglishOxford University Research Archive - ValetPublic Library of Science2011Wegmann, FKrashias, GLühn, KLaamanen, KVieira, SJeffs, SShattock, RSattentau, QProphylactic vaccination against HIV-1 sexual transmission will probably require antibody elicitation at genital mucosal surfaces. However, HIV-1 envelope glycoprotein (Env)-based antigens are weakly immunogenic, particularly when applied mucosally. The polyanion PRO 2000 is safe for human vaginal application, and thus may represent a potential formulating agent for vaginal delivery of experimental vaccine immunogens. Based upon its biochemical properties, we hypothesized that PRO 2000 might enhance mucosal immunogenicity of HIV-1 envelope glycoprotein (Env)-based antigens, promoting local and systemic immune responses. Vaginal immunization with Env-PRO 2000 resulted in significantly increased titres of Env-specific mucosal IgA and IgG in mice and rabbits, respectively, compared to Env alone, revealing modest but significant mucosal adjuvant activity for PRO 2000. In vitro, PRO 2000 associated with Env, protecting the glycoprotein from proteolytic degradation in human vaginal lavage. Unexpectedly, PRO 2000 antagonized TLR4 activation, suppressing local production of inflammatory cytokines. Since inflammation-mediated recruitment of viral target cells is a major risk factor in HIV-1 transmission, the immune modulatory and anti-inflammatory activities of PRO 2000 combined with its intravaginal safety profile suggests promise as an HIV-1 mucosal vaccine formulating agent. |
| spellingShingle | Pathology HIV/AIDS Wegmann, F Krashias, G Lühn, K Laamanen, K Vieira, S Jeffs, S Shattock, R Sattentau, Q A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment |
| title | A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment |
| title_full | A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment |
| title_fullStr | A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment |
| title_full_unstemmed | A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment |
| title_short | A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment |
| title_sort | novel strategy for inducing enhanced mucosal hiv 1 antibody responses in an anti inflammatory environment |
| topic | Pathology HIV/AIDS |
| work_keys_str_mv | AT wegmannf anovelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT krashiasg anovelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT luhnk anovelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT laamanenk anovelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT vieiras anovelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT jeffss anovelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT shattockr anovelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT sattentauq anovelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT wegmannf novelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT krashiasg novelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT luhnk novelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT laamanenk novelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT vieiras novelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT jeffss novelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT shattockr novelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment AT sattentauq novelstrategyforinducingenhancedmucosalhiv1antibodyresponsesinanantiinflammatoryenvironment |